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Abstract
The cellular defense to infection depends on accurate activation of transcription factors and expression of select innate
immunity genes. Interferon regulatory factor 5 (IRF5), a risk factor for systemic lupus erythematosus, is activated in response
to pathogen recognition receptor engagement and downstream effector molecules. We find the nucleotide-binding
oligomerization domain containing protein 2 (NOD2) receptor to be a significant activator of IRF5. Phosphorylation is key to
the regulation of IRF5, but the precise phosphorylation sites in IRF5 remained to be identified. We used mass spectrometry
to identify for the first time specific residues that are phosphorylated in response to TANK-binding kinase-1 (TBK-1), tumor
necrosis factor receptor-associated factor 6 (TRAF6), or receptor interacting protein 2 (RIP2). RIP2, a kinase known to
function downstream of NOD2, was the most effective activator of IRF5-regulated gene expression. To determine if the
phosphorylated residues are required or sufficient for IRF5 activity, aspartic acid phosphomimetic substitutions or
inactivating alanine substitutions were tested. Phosphorylation of carboxyl serines 451 and 462 appear the primary trigger
of IRF5 function in nuclear accumulation, transcription, and apoptosis. Results indicate polyubiquitination of IRF5 does not
play a major role in its transcriptional activity, and that ubiquitination and phosphorylation are independent modifications.
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Introduction
Interferon regulatory factor 5 (IRF5) is an autoimmune
susceptibility factor associated with increased risk of human
systemic lupus erythematosus (SLE) [1,2,3,4,5]. Several animal
disease models have demonstrated the role of IRF5 in autoim-
munity development. Mice that spontaneously develop SLE either
due to an underlying defect in Fas (MRL/lpr) or in the FccRIIB
receptor are protected in the genetic background of IRF5
deficiency [6,7]. IRF5 deficient animals have defects in B cell
differentiation and immunoglobulin isotype switching, which may
highlight a role of IRF5 in autoantibody production characteristic
of SLE [8,9]. In addition, animals with a genetic knockout of IRF5
are protected from lethal shock induced by Toll-like receptor
(TLR) ligands such as nucleic acids or lipopolysaccharide [10].
IRF5 is required for TLR signal transduction to induce
proinflammatory cytokines including tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), and interleukin-12 (IL-12). Multiple
aspects of IRF5 function may impact the complex development of
SLE.
IRF5 is a latent transcription factor with constitutive expression
in lymphocytes, macrophages and dendritic cells [11]. The IRF5
promoter possesses an interferon (IFN) stimulated response
element and a p53 binding site, and has been shown to be
induced in a variety of cell types [11,12,13]. IRF5 is activated from
its latent state by post-translational modifications that include
phosphorylation and ubiquitination [14,15,16,17]. Activation of
IRF5 in response to viral infection has been controversial
[14,15,18]. Our studies indicate that viral infection with Newcastle
Disease Virus (NDV) does not activate IRF5, although expression
of kinases that function during viral infection, TBK-1 or NF-kB
kinase-e (IKKe), can phosphorylate IRF5 [14]. IRF5 has also been
reported to be activated following TLR signaling and engagement
of the TNF receptor associated factor 6 (TRAF6) adapter [10,16].
TRAF6 is an E3 ubiquitin ligase that stimulates K63-linked
ubiquitination and subsequent activation of numerous signaling
molecules and protein kinases, including the receptor-interacting
protein kinase (RIP2) [19,20,21,22]. The RIP2 kinase is known to
be a critical mediator of the innate immune response to nucleotide
oligomerization domain (NOD)-like receptors and to require
ubiquitination [21,23,24,25,26,27]. In summary, TBK-1, TRAF6,
and RIP2 have been implicated in the activation of latent IRF5.
Although phosphorylation appears to be key for IRF5
activation, the specific phosphorylated amino acids that lead to
IRF5 activation remained to be determined. Mass spectrometry
was not used prior to this study to directly identify IRF5
phosphorylation sites. Indications that serine clusters at the
carboxyl terminus were important for activity were suggested
based on homology with IRF3 and targeted mutations [14,28]. In
this study, we have identified specific amino acids by mass
spectrometry that are phosphorylated in response expression of
TBK-1, TRAF6, and RIP2. In addition we have evaluated the
functional impact of site-specific mutations of these IRF5
phosphorylated residues. Substitution with alanine to create loss-
of-function mutations or with aspartic acid to create gain-of-
function mutations were assessed for the ability of IRF5 to induce
gene expression, accumulate in the nucleus, or promote cell death
[14,29]. We further investigated the interplay between phosphor-
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ylation and ubiquitination are independent functional modifica-
tions. Deciphering the molecular modifications that lead to IRF5
activation is expected to provide insight into its diverse functional
roles and open the door for strategic drug design.
Results
Comparison of TBK-1, TRAF6, and RIP2 activation of IRF5
The response of cells to various ligands of pattern recognition
receptors can be complex, involving cross-talk of diverse
downstream signals. Thus in order to evaluate the impact of
specific molecules on IRF5 transcriptional activity, we examined
the effect of TBK-1, TRAF6, or RIP2 co-expression with IRF5 on
a responsive reporter gene. IRF5 is required for induction of a
number of cytokines including interleukin-12, and for this reason
we used a luciferase gene reporter assay regulated by the promoter
of the interleukin-12 (IL-12) p40 subunit gene [10]. The
transfection results with the IRF5 activators are shown in
Figure 1a. Although there was some stimulation by all of the
activators, RIP2 kinase was clearly the most potent. Protein
expression levels of IRF5 were equivalent (Figure S1). Since the
IL12p40 promoter possesses both IRF5 and NF-kB binding sites,
we tested the response of the promoter in which the two NF-kB
binding sites were deleted. The IL12p40dlNF-kB reporter
responded to IRF5 with a similar activation profile as the
IL12p40 reporter gene, affirming the transcriptional function of
IRF5 in this assay (Figure 1b).
The IL-12 p40 gene is a bona fide target of IRF5, but there is
also evidence that IRF5 plays a role in the induction of a subset of
type I interferon (IFN) genes [10,17,30]. To evaluate the
contribution of IRF5 to the induction of IFN genes, we tested
two other reporter genes regulated by either the human IFNa14 or
IFNbpromoter. Both IFN reporters responded to IRF5 activated
by RIP2 kinase, demonstrating IRF5 involvement in the induction
of diverse cytokines (Figure 1c).
TBK-1 modification of IRF5
Phosphorylation of IRF5 appears to activate its ability to induce
transcription of target genes. Since phosphorylation can change
the mobility of proteins during gel electrophoresis, we evaluated
the effect of activators on the migration of IRF5 through SDS-
PAGE. IRF5 was immunoprecipitated from cells co-expressing
TBK-1, TRAF6, or RIP2, separated by gel electrophoresis, and
detected by silver staining (Figure 2a). There was an apparent
decrease in the mobility of IRF5 only with expression of TBK-1.
To more easily examine potential modified forms of IRF5 by gel
electrophoresis we evaluated a smaller IRF5 protein lacking a.a.
1–120 (DN) (Figure 2b). Multiple slower migrating forms of DN
IRF5 were readily apparent only with expression of TBK-1.
To identify the IRF5 residues modified in response to TBK-1,
we used mass spectrometry. Two approaches were used as
described in Methods; in vitro phosphorylation of bacterially
expressed IRF5 by immunocomplexes containing TBK-1, and in
vivo phosphorylation of IRF5 by co-expression with TBK-1 in
tissue culture cells. Modified forms of IRF5 were separated by
SDS-PAGE and submitted for analysis. Two phosphoserines were
identified, S158 and S309 (Figure S2). To determine the
contribution of these modified serines to the slow migrating forms
of IRF5, we analyzed the behavior of alanine substitutions
(Figure 2b). Each individual mutation, S158A or S309A, resulted
in the loss of a distinct modified form and also eliminated the
slowest migrating form, suggesting the slowest form is a result of
dual phosphorylation sites. A double mutation SS158,309AA
Figure 1. IRF5 comparative activation by TBK-1, TRAF6 or RIP2.
a) IRF5 was co-expressed with vector or TBK-1, TRAF6, or RIP2 in
HEK293 cells as indicated, and induction of the IL12p40 luciferase
reporter was measured relative to Renilla gene. Response of IRF5 to
activators was evaluated with increasing transfection ratio of activator
to IRF5: 2-fold, 3-fold, and 4-fold. Values are means of duplicate
determinations in three independent experiments. Protein expression
controls are provided in Figure S1. b) Response of IL12p40 reporter
gene lacking the promoter NF-kB sites (IL12p40dlNF-kB). Induction of
IL12p40dlNF-kB luciferase with 4-fold transfection ratio activator to
IRF5. Luciferase activity was measured as in (a). c) Activation of IRF5 by
RIP2 leads to induction of reporter genes under the control of IL12p40,
IFNa14 and IFNb promoters. Cells were transfected with or without IRF5
and RIP2 as indicated, and induction was measured as in (a).
doi:10.1371/journal.pone.0033098.g001
IRF5 Activation
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TRAF6 and RIP2 do not generate the distinct slow migrating
forms of IRF5 with phosphoserine 158 or phosphoserine 309, it
appears that S158 and S309 are specific phosphorylation sites of
TBK-1, not TRAF6 or RIP2.
IRF5 phosphorylation sites and their role in
transcriptional activity
Although TBK-1 phosphorylation of IRF5 altered its mobility
in SDS-PAGE, the transcriptional activation of IRF5 was more
robust in response to TRAF6 and RIP2. This suggested that
distinct amino acids were phosphorylated in response to TRAF6
and RIP2 that did not alter IRF5 electrophoretic mobility, but
significantly stimulated IRF5 transcriptional potential. To identify
the phosphorylated amino acids that contribute to IRF5
activation, cells were transfected with IRF5 and either TBK-1,
TRAF6, or RIP2. IRF5 was immunoprecipitated from each
transfected cell lysate, combined, separated by SDS-PAGE,
excised, and analyzed by mass spectroscopy. Four additional
phosphorylation sites were identified, two located in a carboxyl
terminal serine cluster (Figure 3a, Figure S2). In summary, we
identified six phosphorylation sites in IRF5; Thr-10 (T10), Ser-158
(S158), Ser-309 (S309), Ser-317 (S317), Ser-451 (S451), and Ser-
462 (S462). To address the contribution of these phosphorylation
sites to IRF5 function, site-directed mutagenesis was performed to
replace each modified amino acid with either alanine or aspartic
acid. Alanine substitution was expected to eliminate effects of
phosphorylation, and aspartic acid substitution could function as a
phospho-mimetic with constitutive activity.
The effects of alanine loss of function substitutions for serine/
threonine in IRF5 were evaluated with the IL12p40 reporter
system and RIP2 (Figure 3b). The most significant effect was found
with the S462A substitution. This single mutation reduced
transcriptional induction by approximately 70% compared with
wt IRF5. The double mutation SS451,462AA further reduced
IRF5 transcriptional activity, and substitution of all six phosphor-
ylated amino acids with alanine (6A) abrogated IRF5 function.
The reduction in activity is not due to differences in protein
expression (Figure S3a). The results indicate S462 as the most
critical phosphorylation site, however other phosphorylation sites
do contribute to IRF5 activity since the 6A mutant is dead in this
assay.
In a converse approach, substitution with aspartic acid can serve
as a phosphomimetic and reveal the positive contribution of the
modified amino acids. Expression of the IRF5 aspartic acid
substitutions in the absence of any activator was tested on
induction of the IL12p40 promoter (Figure 3c). S462D was the
most active single mutation, and combined with S451D,
significantly induced the IL12p40 reporter gene. Notably the
aspartic acid substitution of all six modified residues (6D) showed
maximal activity indicating a modest contribution of other
residues. RIP2 activation of the IRF5 aspartic acid substitutions
showed a similar positive effect of S451D and S462D function in
this assay (Figure 3d). Activity levels are not due to differences in
protein expression (Figure S3b). Considered together, the
substitution mutations indicate two carboxyl terminal serine
residues S451 and S462, particularly S462, are critical for
transcriptional activity of IRF5. The T10, S158, S309, S317
appear to play an auxiliary role.
To evaluate the biological significance of the critical phosphor-
ylation sites in IRF5, we tested the response of IRF5 to activation
by endogenous NOD2 pattern recognition receptors (Figure 4).
NOD2 receptors are activated by muramyl dipeptide (MDP)
which is a component of the peptidoglycan (PGN) cell wall of both
Gram positive and Gram negative bacteria [31,32,33]. We tested
NOD2 receptors since RIP2 is a critical downstream effector of
NOD2 [23,24,25,26], and RIP2 was found to be a potent
stimulator of IRF5 transcriptional activity. Macrophage cells
expressing the IL12p40 reporter with either wt IRF5 or the IRF5
alanine substitution SS451,462AA were treated with either of the
NOD2 natural ligands, MDP or PGN. Results clearly show that in
response to endogenous NOD2 signaling, IRF5 wt induced the
transcriptional activity of the IL12p40 gene. However, the IRF5
mutant that lacks the serines 451 and 462 was not able to induce
gene expression. The results demonstrate natural ligand activation
of NOD2 stimulates IRF5 activity only if the serine residues 451/
462 are available for phosphorylation, confirming the relevance of
the phosphoserines 451 and 462 identified with mass spectrom-
etry.
Phosphorylation regulates IRF5 nuclear trafficking
In a static image latent IRF5 appears in the cytoplasm, however
it dynamically shuttles in and out of the nucleus. This can be
demonstrated by inhibiting IRF5 nuclear export with the
antibiotic leptomycin B (LMB) [14,15,34]. Treatment of cells
with LMB results in nuclear accumulation of latent IRF5, and this
result indicates IRF5 has a constitutive nuclear localization signal
Figure 2. Phosphorylation of IRF5 by TBK-1. a) top) Mobility of
IRF5 in SDS-PAGE with expression of control vector (-), TBK-1, TRAF6, or
RIP2 expressed in HEK293 cells. T7-IRF5 was immunoprecipitated from
cells, separated in SDS-PAGE and visualized by silver staining. Non-
specific (ns) band is indicated. Bottom) Western blot of IRF5 from cells
expressing amino-terminal deletion mutant of T7-IRF5 (121–514a.a.)(DN
IRF5) with vector, TBK-1, TRAF6 or RIP2. Multiple slower mobility forms
of IRF5 are indicated in presence of TBK-1. b) TBK-1 phosphorylation of
IRF5. Site directed mutagenesis of IRF5 was performed to introduce the
single or double mutations in S158A and S309A. Effects of these
mutations on mobility of T7-DN IRF5 in comparison to wt is shown by
Western blot with T7 antibody.
doi:10.1371/journal.pone.0033098.g002
IRF5 Activation
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(NES). The location of two identified NLSs and one NES have
been reported and are shown in Figure 3a [14,15,28]. To function
as a transcription factor, nuclear transport is a critical event. Since
the phosphorylated residue T10 is located near an NLS, and S158
is located within the NES, we evaluated the possible effect of
phosphorylation on IRF5 nuclear trafficking by testing the
phosphorylation site mutants.
IRF5 wt and phosphorylation site mutants were tagged with
GFP to enable direct visualization by fluorescence microscopy.
Cellular localization was observed with or without LMB treatment
to determine the impact of mutations on nuclear import. The
effect of LMB on latent wt IRF5 can be seen to result in nuclear
accumulation, indicating a functional constitutive NLS (Figure 5).
Although T10A and T10D mutations are located near the amino
terminal NLS of IRF5, they had no apparent effect on cellular
localization. However, the S158D mutation in the region of the
NES led to nuclear accumulation in the absence of LMB.
Phosphorylation of S158 may therefore indirectly facilitate nuclear
localization by inhibiting the NES function. However nuclear
accumulation alone with S158D is not sufficient to induce the
IL12p40 gene in the absence of activator (Figure 3c).
Mutations of the other phosphoserines identified by mass
spectrometry were also evaluated for nuclear localization. The
alanine or aspartic acid substitutions for S309, S317, and S462
Figure 3. Effects of phosphorylation site mutations in IRF5. a)
Linear diagram of IRF5 indicating the DNA binding domain (DBD), the
interactive domain (IAD), the nuclear localization signals (NLS), and the
nuclear export signal (NES). The amino acid phosphorylation sites of
IRF5 identified by mass spectrometry are noted (T10, S158, S309, S317,
S451, and S462) (Figure S2). b) The IL12p40 luciferase reporter assay
was used to evaluate the effect of loss-of-function alanine substitutions
in IRF5 in HEK293 cells. Single mutations or double mutations were
introduced in IRF5 and their effect on the IL12p40 luciferase reporter
was measured alone (white bar) or with RIP2 (dark bar). Luciferase
activity is expressed relative to Renilla control and values are means of
three to six independent experiments. *P,0.0001 c) Gain-of-function
mutations were evaluated with aspartic acid substitutions for the
phosphorylated amino acids. Effect of aspartic acid mutations on basal
activity of IRF5 was measured with the IL12p40 luciferase reporter assay
as in (b). *P,0.0001 d) Effect of IRF5 aspartic acid activating mutations
in the absence or presence of RIP2 with the IL12p40 luciferase reporter
assay as in (b).
doi:10.1371/journal.pone.0033098.g003
Figure 4. IRF5 activation by natural ligands of endogenous
NOD2. Wt IRF5, alanine substitution SS451,462AA, or vector control
were co-expressed with the IL12p40 luciferase reporter gene in the
macrophage line RAW264.7. Cells were untreated or treated with
muramyl dipeptide (MDP) or insoluble peptidoglycan (PGN) to
stimulate endogenous NOD2. Luciferase activity was measured as in
Figure 3. Values are means of three independent experiments;
*P,0.0001.
doi:10.1371/journal.pone.0033098.g004
IRF5 Activation
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detectable nuclear IRF5 in 20–30% of the cells. The reason for the
selective nuclear appearance of S451D in a subset of cells remains
to be determined. The double mutant SS451,462DD that
demonstrated significant transcriptional activation of the
IL12p40 gene gained prominent nuclear accumulation indepen-
dent of any activator.
Relationship of IRF5 phosphorylation and ubiquitination
IRF5 was reported to be polyubiquitinated via a K63 ubiquitin
linkage in response to TLR signaling [16]. In that study IRF5
ubiquitination was reported to correlate with its transcriptional
activity and nuclear accumulation. Our objective was to determine
whether phosphorylation was required for ubiquitination or
conversely whether ubiquitination was required for phosphoryla-
tion. To evaluate a possible interdependence, we first determined
whether activation by RIP2 or TBK-1, stimulated the ubiquitina-
tion of IRF5 as did TRAF6. We co-expressed His-tagged IRF5
with these different activators and HA-tagged ubiquitin. IRF5 was
isolated by affinity to Ni-NTA-agarose beads and evaluated by
Western blot (Figure 6a). High molecular weight modified forms of
IRF5 were obvious with co-expression of RIP2 and TRAF6, but
Figure 5. Cellular localization of wt IRF5 and phosphorylation mutants. Fluorescence imaging was used to evaluate cellular localization of
wt GFP-IRF5 or point mutants in GFP-IRF5 expressed in HT1080 cells. Effects of amino acid substitutions with alanine (A) or aspartic acid (D) are shown
in absence or presence of export inhibitor leptomycin B (LMB). *Asterisk notes significant gain of nuclear accumulation with S158D and SS451,462DD.
Images represent random sampling of 12 to 15 fields and reflect more than 80% of the population in three independent experiments.
doi:10.1371/journal.pone.0033098.g005
IRF5 Activation
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confirmed these modified forms of IRF5 to be polyubiquitinated.
It remained to be determined whether specific phosphorylation
of IRF5 was required for its ubiquitination, or whether
ubiquitination was sufficient for IRF5 activation. To evaluate
these relationships we analyzed the IRF5 SS451,462AA (C9-2A)
mutation that cannot be phosphorylated on the carboxyl serines,
and the IRF5 SS451,462DD (C9-2D) mutation that is transcrip-
tionally active (Figure 6b). TRAF6 was used as an activator of wt
or mutant IRF5. The SS451,462AA mutant that is transcription-
ally dead and cannot be phosphorylated at the critical serines was
polyubiquitinated. Therefore although phosphorylation of these
carboxyl serines is required for IRF5 transcriptional activity,
phosphorylation of these residues is not required for ubiquitina-
tion. Polyubiquitin chains with different lysine linkages promote
distinct effects; ubiquitin lysine 48 linkage targets substrates for
degradation, whereas lysine 63 linkage promotes effects that
include signaling and trafficking [35]. To determine the presence
of K63-ubiquitination, IRF5 was co-expressed with HA-tagged
ubiquitin that had all lysines substituted with arginine except lysine
63 (HA-K0R63K). Results showed both SS451,462AA (C9-2A)
and SS451,462DD (C9-2D) were modified by K63 polyubiquitina-
tion (Figure S4). Together the results indicate phosphorylation is
not required for ubiquitination, and ubiquitination itself is not
sufficient for IRF5 transcriptional activity.
To further investigate the interplay between phosphorylation
and ubiquitination of IRF5, we tested the effect of the ubiquitin-
editing enzyme A20, known to possesses K63-deubiquitinating
activity [36,37,38]. RIP2 was used as an upstream activator of
IRF5 and the effect of A20 co-expression was evaluated on the
ability of wt IRF5 to induce the IL12p40 reporter gene (Figure 7a).
A20 decreased the ability of RIP2 to stimulate IRF5 transcrip-
tional activity. This result could be due to deubiquitination of
IRF5 or RIP2 [21,23,27,39]. If IRF5 requires ubiquitination for
activity, the constitutively active SS451,462DD mutant would also
be inhibited by A20. However, the active phosphomimetic mutant
was resistant to A20 expression (Figure 7a). These results suggest
continuous K63-ubiquitination of IRF5 is not required for IRF5
transcriptional activity.
Another line of evidence indicated that direct ubiquitination of
IRF5 is not necessary for its transcriptional function. Specific
lysine residues of IRF5 were previously reported to be required for
K63-ubiquitination (designated K410, K411) [16]. To test the
requirement of these lysines for transcriptional activity, we
Figure 6. Ubiquitination of IRF5. a) Ubiquitination of wt IRF5 in response to RIP2, TBK-1, or TRAF6. His-tagged IRF5 or vector (v) and HA-tagged
ubiquitin were expressed individually or co-expressed in HEK293 cells with myc-tagged RIP2, TBK-1, or TRAF6. IRF5 was captured from lysates by Ni
++-
NTA agarose beads and evaluated by Western/immunoblot blot (IB) for ubiquitination with anti-HA (IB:HA-Ub) or anti-IRF5 antibodies. Lysate input to
Ni
++-NTA beads is shown by Western blot with anti-IRF5, anti-RIP2, and anti-myc for TBK-1, TRAF6, and anti-tubulin. b) Polyubiquitination of wt IRF5,
IRF5 SS451,462AA (C9-2A), or IRF5 SS451,462DD (C9-2D) with TRAF6 co-expression. His-tagged IRF5 constructs or vector co-expressed with HA-
ubiquitin were collected on Ni
++-NTA agarose beads as in (a). Polyubiquitination was detected by Western/immunoblot (IB) blot with anti-HA (IB:HA-
Ub). Lysate input to Ni
++-NTA beads is shown for IRF5 and tubulin.
doi:10.1371/journal.pone.0033098.g006
IRF5 Activation
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generate KK/RR. Although activity was reduced in comparison
to wt IRF5, IRF5 KK/RR was able to significantly increase
transcription of the reporter gene (Figure 7b). Indeed if the KK/
RR mutation was combined with the activating SS451,462DD
mutation, the double mutant had full transcriptional activity in the
presence of RIP2 in comparison to wt IRF5. These data indicated
that the lysine residues identified as ubiquitination target sites in
IRF5 are not required for transcriptional activity. Results are not
due to differences in protein expression (Figure S5). Together the
data suggest that ubiquitination and phosphorylation are inde-
pendent modifications, and the critical commitment for IRF5
nuclear accumulation and transcriptional activation is phosphor-
ylation of the carboxyl serines 451 and 462.
Phosphorylation affects IRF5-mediated apoptosis
Studies by our group and others have linked expression of IRF5
with another cellular function, the promotion of apoptosis
[14,29,40,41]. To determine if the specific phosphorylation of
IRF5 contributes to its pro-apoptotic effects, we evaluated the
IRF5 aspartic acid gain-of-function mutations. Cells expressing wt
IRF5 or the IRF5 mutants tagged with GFP were analyzed with
flow cytometry for cell death by permeability to propidium iodide
(Figure 8a) or for apoptosis by staining with annexin V (Figure 8b)
[42]. Expression of wt IRF5 had a modest effect on cell death,
however the transcriptionally active SS451,462DD mutation had a
dramatic pro-apoptotic effect. The promotion of apoptosis
correlated with the transcriptional activity of SS451,462DD.
Unexpectedly the S158D mutation that did not transcriptionally
induce the IL12p40 gene, also promoted apoptosis, albeit to a
lesser extent. The S158D mutation is within the NES of IRF5 and
localize the protein to the nucleus presumably due to an inhibition
of nuclear export (Figure 5). The results indicate both transcrip-
tional activation and nuclear presence contribute to the pro-
apoptotic effects of IRF5. The increases in apoptosis seen with
these aspartic acid mutants were not due to differences in protein
expression (Figure S6).
Discussion
Engagement of pattern recognition receptors (PRRs) stimulates
innate immune responses that promote clearance of microbial
infections, but in addition these responses can contribute to
inflammation and autoimmunity [43,44]. IRF5 has been shown to
respond to TLR and NOD signaling, and polymorphisms of IRF5
are associated with increased risk of autoimmune disease
[1,3,4,5,9,10,17]. Since IRF5 may be a potential target of
autoimmune intervention, knowledge of the mechanisms that
activate IRF5 is needed [21,30,45]. Post-translation phosphoryla-
tion has been shown to regulate the molecular switch in IRF5 from
latency to activation, however the precise phosphorylation sites in
IRF5 remained to be determined. In this study we identified
amino acids in IRF5 that are phosphorylated in response to
signaling molecules downstream of PRRs. Our subsequent
mutagenesis studies clearly establish the contribution of IRF5
modified amino acids to transcriptional induction, nuclear
trafficking, and apoptosis.
We investigated the effects of several potential activators of
IRF5; TBK-1, TRAF6, and RIP2. TBK-1 was previously
identified as a kinase that phosphorylates the carboxyl terminus
of the related transcription factor, IRF3, in response to viral
infection [46,47,48,49,50]. TRAF6 is an E3-K63 ubiquitin ligase
that can activate effector enzymes downstream of TLR and NOD
signaling [19,20,51]. RIP2 kinase plays an essential role in the
biological responses to NOD signaling [21,23,52]. We tested the
effect of these activators on induction of the IL12 p40 subunit gene
by IRF5. TBK-1 had a modest effect on the ability of IRF5 to
induce the IL12p40 reporter, however TRAF6 and especially
RIP2 were far more effective activators of IRF5 (Figure 1).
Although the gene induction by IRF5 in the presence of TBK-1
was modest, phosphorylation by TBK-1 produced a significant
shift in the mobility of IRF5 in SDS-PAGE. For this reason we
identified the residues that are phosphorylated on IRF5 by TBK-1
with mass spectrometry. Ser-158 and Ser-309 were found to be
phosphorylated, and mutations of these serines eliminated specific
shifts in IRF5 mobility by SDS-PAGE. These residues did not
appear to be modified by TRAF6 or RIP2. In addition, these
residues did not reside in the carboxyl terminus of IRF5, a region
that was expected to contribute to its modification and activation
[14,53].
TRAF6 and especially RIP2 were far more effective activators
of IRF5 than TBK-1 (Figure 1), and mass spectrometry identified
Figure 7. Activity of IRF5 SS451,462DD independent of
ubiquitination. a) The activity of wt IRF5 or IRF5 SS451,462DD on
the IL12p40 luciferase reporter assay was evaluated in the presence or
absence of RIP2 with increasing expression of A20 (1-fold, and 1.33-fold
relative to RIP2). Luciferase activity was measured relative to co-
transfected Renilla gene. b) IRF5 activity independent of the
characterized ubiquitination site at K410,K411 in IRF5 v4. KK410,411RR
site mutation in IRF5 v4 is equivalent to KK427,428RR in IRF5 v5.
Induction of the IL12p40 luciferase reporter gene by wt IRF5, IRF5 KK/
RR, or IRF5 KK/RR, SS451,462DD (KK/RR, SS/DD) with or without
expression of RIP2. The data is presented relative to Renilla control and
vector alone (v). Values are means of duplicate determinations in two
independent experiments.
doi:10.1371/journal.pone.0033098.g007
IRF5 Activation
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RIP2. In total, six phosphorylated residues were identified in IRF5
in response to co-expression of upstream activators TBK-1,
TRAF6, and RIP2: Thr-10, Ser-158, Ser-309, Ser-317, Ser-451,
and Ser-462 (Figure 3). To determine the contribution of each of
these amino acids to the transcriptional function of IRF5, each was
substituted with alanine to evaluate loss-of-function or with
aspartic acid to evaluate a gain-of-function. Judging by the effect
of the mutations, S462D stimulated considerable gene induction in
the absence of activators while S462A had a severe negative effect
on IRF5. There was also a cooperative effect of S462D with
S451D, supporting the tenet that phosphorylation of carboxyl
serine residues is a key element for IRF5 activity [14,28,53].
Although these two phosphoserines are the critical modifications,
phosphorylation of other residues outside the carboxyl terminus
plays an auxiliary role. This is demonstrated by the most
significant effects with substitution of all of the modified residues
as 6A or 6D. Although IRF5 6D stimulated significant gene
expression, the addition of RIP2 boosted the response. This may
be due to other transcription factors stimulated by RIP2 that can
interact directly with IRF5 or augment IRF5 effects indirectly.
The cellular response to pathogens via PRRs results in stimulation
of complex signal pathways and activation of diverse adapters,
ubiquitin ligases, and kinases. Pathogens can also activate different
PRRs coordinately, promoting pathway cross-talk. The multiple
phosphorylation sites on IRF5 may reflect an evolved response to
activation of diverse PRRs and kinases.
As a transcription factor IRF5 must gain entrance to the
nucleus, and nuclear transport is one mode of regulation.
Although IRF5 has two reported NLSs and is transported to the
nucleus continually, it also has a dominant NES [14,15,28].
Therefore the latent IRF5 protein continually shuttles in and out
of the nucleus, but is prominent in the cytoplasm. We evaluated
the effect of the substitution mutants on the cellular localization of
IRF5 (Figure 5). The SS451,462DD double mutant showed
dominant accumulation in the nucleus in the absence of activators.
This was not unexpected since the double mutant is transcrip-
tionally active. However, there were some unexpected findings.
The S462D mutant did not accumulate in the nucleus although it
induced gene expression independent of activators. It is possible
that the continuous nuclear shuttling of S462D provides sufficient
residence time in the nucleus to effect gene expression. The S451D
activating mutant accumulated in the nucleus of only 20–30% of
the expressing cells. The reason for the heterogeneity of
localization in the culture remains to be determined. In addition,
another phosphomimetic mutation was prominently nuclear,
S158D. This was unexpected since this modification did not
activate IRF5’s transcriptional activity. However, serine 158 is
located within the IRF5 NES (LQRMLPSLSLT), and so the result
suggests that the serine phosphorylation impairs nuclear export of
IRF5.
Since K-63 polyubiquitination was reported to be necessary for
IRF5 activation, we investigated the relationship between IRF5
phosphorylation and ubiquitination [16]. TRAF6 and RIP2,
potent activators of IRF5 transcriptional activity, were found to
stimulate IRF5 ubiquitination whereas TBK-1 did not (Figure 6).
To determine whether the phosphorylation of the activating
carboxyl serines was necessary for ubiquitination, we evaluated
TRAF6 ubiquitination of SS451,462AA in comparison with
SS451,462DD or wt. Polyubiquitination of SS451,462AA was
clearly detectable, demonstrating that phosphorylation of these
serines is not required for ubiquitination.
We used two other approaches to evaluate ubiquitination and
transcriptional activity of IRF5 (Figure 7). A20 is an ubiquitin-
Figure 8. Pro-apoptotic effect of constitutively active IRF5
mutants. a) HeLa cells were transfected with plasmids encoding GFP
vector (v), wt GFP-IRF5 (WT) or GFP-IRF5 double mutant SS451,462DD.
Cells were stained with propidium iodide after one, two, or three days
post-transfection and cells positive for GFP and PI were quantified by
flow cytometry. b) Cells were transfected as in (a) and were stained with
annexin V. Cells positive for GFP and annexin V were measured by flow
cytometry. c) Three days following transfection with GFP vector, wt
GFP-IRF5, or GFP-IRF5 with the noted activating aspartic acid
substitutions cells were stained with annexin V. Cells positive for GFP
and annexin V were quantified by flow cytometry. All results are means
of triplicate determinations in three independent experiments.
doi:10.1371/journal.pone.0033098.g008
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to inhibit signaling from the PRRs [27,55,56]. When co-expressed
with RIP2, it inhibited the ability of wt IRF5 to induce
transcription. To determine if A20 impacted upstream signaling
molecules like RIP2 or directly influenced IRF5, we tested the
constitutively active mutant, SS451,462DD in the absence of
RIP2. The A20 deubiquitinase did not reduce the transcriptional
activity of SS451,462DD, suggesting ubiquitination is not
necessary for IRF5 activity. A second approach was to evaluate
the effect of lysine mutations in IRF5 reported to be targets of
ubiquitination. The TRAF6 K63-ubiquitination site in IRF5v4
has been identified and characterized [16,28]. We tested IRF5
activity following mutation of these corresponding lysines in
IRF5v5 (KK427,K428RR) (KK/RR). Although the transcription-
al activity of IRF5 KK/RR was 2-fold less than wt, IRF5 KK/RR
was still activated by RIP2, and activity was complete in the
context of the activating mutation (KK/RR, SS/DD). Together,
the results indicate that carboxyl terminal phosphorylation of
IRF5 and not ubiquitination is the critical modification that
determines IRF5 transcriptional activity.
Since another property of IRF5 is its ability to promote
apoptosis, we tested the effects of substitution mutants on this
function (Figure 8). Expression of the transcriptionally active
mutant SS451,462DD was found to stimulate an apoptotic cell
death. This finding was not unexpected since the ability of IRF5 to
regulate transcription may be linked to pro-apoptotic gene
expression. However, another phosphomimetic mutation that
significantly enhanced cell death was S158D. This was unexpected
since S158D was not transcriptionally active in our assay.
However S158D did accumulate in the nucleus, and therefore
its ability to promote apoptosis may indicate that this modification
allows IRF5 to interact with other nuclear factors that influence
cell death. This mechanism of action remains to be determined.
Phosphorylation of IRF3, IRF5, and IRF7 triggers a conforma-
tional change that promotes dimerization and binding to CBP/
p300 [48,53,57]. Several isoforms of IRF5 have been identified,
most resulting from alternative splicing [14]. We have investigated
variant 5, the longest form of IRF5, and amino acid numbering is
relative to this isoform. The crystal structure of a fragment of IRF5
(a.a. 222–467) has been solved with variant 4 (v4) using a
phosphomimetic substitution S430D, which corresponds to serine
456 in variant 5 (v5) [53]. Our mass spectrometry results did not
identify phosphorylation oftheserine456v5,butphosphorylation of
flanking serines, 451v5 and 462v5. Although the crystal structure of
IRF5 was not solved with an authentic phosphorylation site, certain
predictions can be made from their analyses. The structural data
predicts phosphorylation of serine 451v5 contributes to destabiliza-
tion of the autoinhibitory conformation of IRF5. Our results with a
phosphomimetic of this serine (S415D) showed an increase in
transcriptional activity and a modest increase in nuclear accumu-
lation. The crystal structure predicts phosphorylation of serine
462v5 plays a significant role in stabilization of the formed IRF5
dimers [53]. The serine 462v5 is positioned within hydrogen
bonding distance of arginine 354v5, an arginine that is conserved in
human IRF3 and IRF7. Our results with the phosphomimetic
S462D demonstrated a considerable increase in transcriptional
activity. More significantly, a phosphomimetic substitution of both
serine 451 and 462 together (SS451,462DD) provided a dramatic
increase in nuclear accumulation, transcriptional activity, and pro-
apoptotic effects. These data support the tenet that phosphorylation
of serine 451 relieves the autoinhibitory conformation, and
phosphorylation of serine 462 stabilizes the IRF5 dimers.
Phosphorylation of these serines together serves as a trigger for
conformational change and dimerization.
In this study our objective was to elucidate the molecular
modifications that regulate IRF5 transition from latency to an
active transcription factor. For the first time specific phosphory-
lation sites of IRF5 have been identified by mass spectrometry, and
their contributions to gene induction and apoptosis have been
evaluated. In addition, the effectiveness of RIP2 as an upstream
activator of IRF5 suggests that IRF5 plays a preferential role in
NOD-like receptor signaling. This knowledge advances our
understanding of the molecular mechanisms that trigger IRF5
activity in health and disease.
Materials and Methods
Cell Culture and reagents
Human HEK293, HT1080, HeLa and murine RAW264.7 cells
were obtained from ATCC. Cells were grown in Dulbecco’s
modified Eagle’s medium with 8% fetal bovine serum, penicillin
(100 U/ml) and streptomycin (100 mg/ml) (Invitrogen). To
measure the effect of NOD2 signaling, 50 mg/ml of muramyl
dipeptide (MDP) or 15 mg/ml insoluble peptidoglycan (InvivoGen)
wasadded to RAW264.7cultures.LeptomycinB (LMB)wasused at
10 ng/ml (gift from B. Wolff-Winiski, Novartis Research Institute).
Expression plasmids
Plasmids T7-His-tagged pcDNA3 vector, T7-His-tagged
IRF5v.5, GFP-IRF5, and FLAG-TBK-1 have been described
[14]. The T7-His-tagged DN IRF5 was generated by PCR (primers
in Table S1). The DN IRF5 DNA fragment spanning from 201 to
514 amino acids of IRF5 was subcloned into the T7-His-pcDNA3
and verified by sequencing. IRF5 point mutants were constructed
using primers (Table S1) by Quick Change mutagenesis kit
(Stratagene) and verified by sequencing. His-tagged DNIRF5 was
cloned into bacterial expression vector pET-15b (Novagen).
Luciferase reporter genes were driven by the human IFNa14
promoter (2457 to +71) (Dr. Racine Brzostek, Stony Brook
University) and IFNb promoter [14]. The following plasmids were
generous gifts: FLAG-TBK-1 (Dr. Michael Karin, University of
California San Diego); c-myc-TBK-1 (Dr. Erich Mackow, Stony
Brook University); c-myc-TRAF6 (Dr. John Reed, Burnham
Institute); HA- or omni-tagged-RIP2 (Dr. Derek Abbott, Case
Western Reserve University) [39]; IL12p40 and IL12p40dlNF-kB
luciferase reporter genes (Dr. Keiko Ozato, NIH) [58]; HA-tagged
ubiquitin (HA-Ub) and HA-tagged K0R63K (HA-K63Ub) (Dr.
Dafna BarSagi, New York University) [59]; A20 (Dr. Anatoly
Grishin, University of Southern California) [56].
Transfection and Luciferase reporter assay
Transfection of RAW264.7 cells was performed by electropo-
ration (Amaxa Cell Line Nucleofector Kit V, Lonza). HEK293,
HT1080 and HeLa were transfected using TransIt-LT1 transfec-
tion reagent (Mirus; Madision, WI, USA). The luciferase activity
was measured by a Lumat model LB 9507 luminometer using
Dual-Luciferase Reporter Assay System (Promega). Results were
normalized to co-transfected pRLTK reporter gene (Renilla
luciferase, Promega; Madison, WI, USA). Values are means of
three to six independent experiments, and bars show one standard
error of the mean, and are expressed as the activity relative to
pcDNA3 alone.
Direct Fluorescence imaging
HT1080 cells on coverslips were transfected with GFP-IRF5
constructs and 24 hours later treated with leptomycin B for
1 hour. Cells were fixed in 3.7% formaldehyde/PBS and stained
with 2 mg/ml of Hoechst 33342 at room temperature for
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antifade solution (Vector Laboratories; Burlingame, CA). GFP-
tagged proteins were observed with Zeiss Axiovert 200M and
Axiovision Version 4.5 and images captured with Adobephoto-
shop.
Apoptosis assay
HeLa cells were transfected with GFP-IRF5 constructs, washed
with media six hours post-transfection, and cell death was
measured 1, 2 or 3 days post-transfection by propidium iodide
staining and evaluation with a FACSCalibur flow cytometer (BD
Biosciences, Breda, The Netherlands) [42]. Apoptosis was
evaluated by staining with allophycocyanin (APC)-conjugated
annexin V (BD Pharmingen; San Diego, CA) and flow cytometry.
The gate was set for GFP expression, and 10,000 cells in each
population were analyzed with BD CellQuest software.
Immunoprecipitation, Silver Staining and Western blot
Antibodies used included anti-IRF5 (ProteinTech Group Inc.;
Chicago, IL), anti-T7 (Novagen), anti-RIP2 (sc-22763, Santa Cruz
Biotechnology), anti-omni (sc-7270, Santa Cruz Biotechnology),
anti-c-Myc (sc-40, Santa Cruz Biotechnology), anti-HA (12CAS,
Roche), anti-FLAG (F3165, Sigma), and secondary anti-mouse
(Rockland) and anti-rabbit (Invitrogen) antibodies for Western blot
analysis with Odyssey Imager (Li-COR Biosciences). For immu-
noprecipitation, cells were lysed in 50 mM Tris (pH 7.5), 400 mM
NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 50 mM sodium
fluoride, 10% glycerol, 10 mM b-glycerolphosphate, 1 mM
sodium vanadate, 1 mM PMSF and protease inhibitor mixture
(Sigma-Aldrich). Lysates were clarified by centrifugation at
12,000 g for 10 min prior to antibody addition. Immunocom-
plexes were collected with protein-G beads, eluted, and separated
on 8.5% SDS-PAGE. Proteins were transferred to Immobilon-P
(Millipore) for Western blotting and reactive signals were detected
with the Odyssey Imager (Li-COR Biosciences) and analyzed
using Image J software (NIH). Alternatively, secondary antibodies
linked to HRP were used (Amersham/GE Healthcare) and the
membrane was incubated in enhanced chemiluminescence
reagents and exposed to film. Proteins visualized without Western
blotting were detected by silver staining (SilverQuest, Invitrogen)
Ubiquitination assays
HEK293 cells were co-transfected with plasmids encoding His-
tagged IRF5 and c-myc-tagged TBK-1 or c-myc-tagged TRAF6
or HA-tagged RIP2 with wild type HA-tagged ubiquitin or HA-
tagged K0R63K ubiquitin. 48 hours post-transfection cells were
harvested and His-tagged IRF5 proteins were isolated on Ni-NTA
agarose beads (Qiagen). Elutes from the Ni-NTA agarose beads
were subjected to 8.5% SDS-PAGE analysis and Western blot.
Mass Spectrometry Analysis
Analysis of IRF5 phosphorylated amino acids by TBK-1 was
performed with two approaches. Bacterially expressed and
purified His-tagged DNIRF5 was phosphorylated in vitro by
FLAG-TBK-1 immunoprecipitated from mammalian HEK293
cells. Proteins were separated on 7.5% SDS-PAGE and detected
by Coomassie brilliant blue staining. A slower mobility IRF5
protein band was provided to the University of Massachusetts
Medical School Proteomics Lab for in gel protein cleavage with
trypsin and analysis by LS/MS/MS. Their data interpretation
indicated phosphorylation of serine 156 or 158 and we confirmed
158 was modified by mobility shift analyses (Figure S2). In vivo
phosphorylation of T7-His-IRF5 S158A mutant was analyzed by
co-expression with FLAG-TBK-1 in HeLa cells. T7 antibodies
conjugated to agarose beads (Novagen) were used to collect T7-
IRF5 immunocomplexes from cell lysates. IRF5 was visualized in
SDS-PAGE by staining with SimplyBlue (Invitrogen), and slow
mobility IRF5 protein band was eluted, treated with iodoaceta-
mide, and submitted for analysis to ProtTech Inc. (Norristown,
PA). The sample was digested with trypsin and chymotrypsin to
generate peptides that were reconstituted in 2% acetynitrile,
100 mM fumic acid pH 3.0, and analyzed by nano LC-MS/MS
system for sequencing. A high-pressure liquid chromoatography
C18 column was coupled with an ion-trap mass spectometer. The
MS/MS data were analyzed with Protech’s proprietary software.
Peptide containing IRF5 serine 309 was identified by LS/MS/MS
to be phosphorylated in the presence of TBK-1 in vivo. Additional
in vivo phosphorylation analyses were performed by co-transfection
of T7-His-IRF5 with either myc-TBK-1, myc-TRAF6, or HA-
RIP2 in HEK293 cells. IRF5 was collected on T7 antibody
agarose beads from the individual transfections, eluted, and
subsequently pooled. Proteins were separated by SDS-PAGE,
visualized with Commassie brilliant blue stain, treated with
iodoacetamide, and submitted for analysis to ProtTech Inc. as
described. Peptide analyses by LS/MS/MS identified additional
phosphorylated amino acids corresponded to threonine 10, serine
309, serine 451, and serine 462. The detectable b-type and y-type
fragment ions for the phosphopeptides were annotated in Figure
S2, and bold print indicates key fragments to facilitate identifica-
tion of phosphorylation residues.
Supporting Information
Figure S1 Transfection controls for protein expression
in Figure 1a. Cell lysates from a transfection shown Figure 1a
indicate similar levels of IRF5 are expressed with co-expression of
c-myc-tagged TBK-1, c-myc-tagged TRAF6 or omini-tagged
RIP2. Western blots with anti-IRF5, anti-myc or anti-omni
antibodies.
(TIF)
Figure S2 IRF5 phosphorylated amino acids identified
by LC-MS/MS. Phosphopeptides identified are shown with
specific phosphorylated threonine or serine. a–e) Identification of
in vivo phosphorylated amino acids, threonine 10, serine 309,
serine 317, serine 451, and serine 462 by ProtTech, Inc. following
IRF5 immunoprecipitation from HEK293 cells expressing TBK1,
TRAF6, and RIP. (see Methods). f) Identification of serine 158
phosphorylation by in vitro kinase reaction with TBK-1. Analysis
by University of Massachusetts Proteomics Lab.
(TIF)
Figure S3 Transfection controls for IRF5 expression in
Figure 3. Expression levels of wt IRF5 and IRF5 mutations in
absence or presence of omini-tagged RIP2 are similar in luciferase
reporter studies shown in Figure 3b (a) and 3d (b). Western blots
with anti-IRF5, anti-omni or anti-tubulin antibodies.
(TIF)
Figure S4 Polyubiquitination of IRF5 via ubiquitin
lysine 63. Assay performed as described in Fig. 6b. With co-
expression of HA-tagged ubiquitin K0R63K (K63Ub).
(TIF)
Figure S5 Expression controls for IRF5 in Figure 7.
Expression levels are similar for wt IRF5, IRF5 KK427,428RR
(KK/RR), and IRF5 KK427,428RR, SS451,462DD (KK/RR,
SS/DD). Proteins from an experiment of Figure 7 were evaluated
by Western blot with indicated antibodies.
(TIF)
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studies of Figure 8. Western blot of cell lysates from experiment
shown in Figure 8c with anti-IRF5 or anti-tubulin antibodies.
(TIF)
Table S1 Oligonucleotide primers for plasmid genera-
tion. Single stranded forward primer DNA sequences are shown
(59 to 39) that were used to introduce mutations in the IRF5 DNA
sequence.
(PDF)
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